Glaxo (NYSE:GSK) recently announced that it is initiating a phase III program consisting of two studies, namely COMBI-d and COMBI-v. The studies are aimed at evaluating the safety and efficacy of dabrafenib (2118436, BRaf inhibitor) and trametinib (1120212, MEK inhibitor) combination therapy in patients with BRaf mutation-positive metastatic cutaneous melanoma.
The COMBI-d phase III study will compare the combination of dabrafenib and trametinib with dabrafenib alone. The study will evaluate the … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here